| abstract |
A process for inducing tolerance to an antigen in a patient comprising administering to said patient an effective amount of an anti-CD40L antibody over a period of up to 4 weeks without subsequent re-administration after this period for at least 6 months, wherein the antibody consists of Fab or F(ab') 2 fragments or contains mutations in the Fc region which prevent binding of the antibody to Fc receptors. Chimeric anti-CD40L antibodies and uses thereof. |